Grace, C. et al. Trends of outpatient prescription drug utilization in US children, 2002–2010. Pediatrics 130, 23–31 (2012).
Nymark, T. B., Hovland, A., Bjørnstad, H. & Nielsen, E. W. A young man with acute dilated cardiomyopathy associated with methylphenidate. Vasc. Health Risk Manag. 4, 477–479 (2008).
Dadfarmay, S. & Dixon, J. A case of acute cardiomyopathy and pericarditis associated with methylphenidate. Cardiovasc. Toxicol. 9, 49–52 (2009).
Hole, L. D. & Schjott, J. Myocardial injury in a 41-year-old male treated with methylphenidate: a case report. Drug Saf. 37, 661–676 (2014).
Munk, K., Gormsen, L., Kim, W. Y. & Andersen, N. H. Cardiac arrest following a myocardial infaction in a child treated with methylphenidate. Case Rep. Pediatr. 2015, 905097 (2015).
Vetter, V. L. et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117, 2407–2423 (2008).
Perrin, J. M., Friedman, R. A. & Knilans, T. K., Black Box Working Group, Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 122, 451–453 (2008).
American Academy of Pediatrics/American Heart Association. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J. Dev. Behav. Pediatr. 29, 335 (2008).
Gould, M. S. et al. Sudden death and use of stimulant medications in youths. Am. J. Psychiatry 166, 992–1001 (2009).
Nissen, S. E. ADHD drugs and cardiovascular risk. N. Engl. J. Med. 354, 1445–1448 (2006).
Kuehn, B. M. Stimulant use linked to sudden death in children without heart problems. JAMA 302, 613–614 (2009).
Newcorn, J. H. & Donnelly, C. Cardiovascular safety of medication treatments for attention-deficity/hyperactivity disorder. Mt. Sinai J. Med. 76, 198–203 (2009).
Olfson, M. et al. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 51, 147–156 (2012).
Bange, F., Le Heuzey, M. F., Acquaviva, E., Delorme, R. & Mouren, M. C. Cardiovascular risks and management during attention deficit hyperactivity disorder treatment with methylphenidate. Arch. Pediatr. 21, 108–112 (2014).
Shin, J. Y., Roughead, E. E., Park, B. J. & Pratt, N. L. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series. BMJ 353, i2550 (2016).
Hennissen, L. et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs 31, 199–215 (2017).
Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich, M. et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128, 1007–1022 (2011).
Take, G. et al. Dose-dependent immunohistochemical and ultrastructural changes after oral methylphenidate administration in rat heart tissue. Anat. Histol. Embryol. 37, 303–308 (2008).
Henderson, T. A. & Fischer, V. W. Effects of methylphenidate (Ritalin) on mammalian myocardial ultrastructure. Am. J. Cardiovasc. Pathol. 5, 68–78 (1995).
Witt, K. L. et al. No increases in biomarkers of genetic damage or pathological changes in heart and brain tissue in male rats administered methylphenidate hydrochloride (Ritalin) for 28 days. Environ. Mol. Mutagen. 51, 80–88 (2010).
Zhang, X. et al. MicroPet/CT assessment of FDG uptake in brain after long-term methylphenidate treatment in nonhuman primates. Neurotoxicol. Teratol. 56, 68–74 (2016).
Morris, S. M. et al. The genetic toxicology of methylphenidate hydrochloride in non-human primates. Mutat. Res. 673, 59–65 (2009).
Mattison, D. R. et al. Pubertal delay in male nonhuman primates (Macaca mulatta) treated with methylphenidate. Proc. Natl Acad. Sci. USA 108, 16301–16306 (2011).
Rodriguez, J. S. et al. The effects of chronic methylphenidate administration on operant test battery performance in juvenile rhesus monkeys. Neurotoxicol. Teratol. 32, 142–151 (2010).
Yang, X. et al. Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates. PLoS ONE 9, e106101 (2014).
Matsuzawa, T. & Nagai, Y. Comparative haematological and plasma chemistry values in purpose-bred squirrel, cynomolgus and rhesus monkeys. Comp. Haematol. Int 4, 43–48 (1994).
https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/35110. Accessed 25 Feb 2018.
Sallach, S. M. et al. Change in serum myoglobin to detect acute myocardial infarction in patients with normal troponin I levels. Am. J. Cardiol. 94, 864–867 (2004).
Keltz, E., Fahmi, Y., Khan, Y. & Mann, G. Rhabdomyolysis. The role of diagnostic and prognostic factors. Muscles Liga. Tendons J. 3, 303–312 (2013).
Olerud, J. E., Homer, L. D. & Carroll, H. W. Incidence of acute exertional rhabdomyolysis: serum myoglobin and enzyme levels as indicators of muscle injury. Arch. Intern. Med. 136, 692–697 (1976).
Reuter, J. D., Dysko, R. E. & Crisp, C. E. Review of exertional rhabdomyolysis in a rhesus monkey (Macaca mulatta). J. Med. Primatol. 27, 303–309 (1998).
Findling, R. L. et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J. Pediatr. 147, 348–354 (2005).
Donner, R., Michaels, M. A. & Ambrosini, P. J. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder. Biol. Psychiatry 61, 706–712 (2007).
Wilens, T. E., Biederman, J. & Lerner, M. Effects of once-daily osmotic release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J. Clin. Psychopharmacol. 24, 36–41 (2004).
Wilens, T. E., Spencer, T. J. & Biederman, J. Short- and long-term cardiovascular effects of mixed amphetamine salts extended-release in adolescents with ADHD. CNS Spectr. 10(Suppl. 15), 22–30 (2005).
Biederman, J. et al. A randomized, placebo-controlled trial of OROS methyphenidate in adults with attention-deficit disorder. Biol. Psychiatry 59, 829–835 (2006).
Schelleman, H. et al. Methylphenidate and risk of serious cardiovascular events in adults. Am. J. Psychiatry 169, 178–185 (2012).
Schelleman, H. et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 127, 1102–1110 (2011).
Habel, L. A. et al. ADHD drugs and serious cardiovascular events in children and young adults. JAMA 365, 1896–1904 (2011).
Lipshultz, S. E., Cohen, H., Colan, S. D. & Herman, E. H. The relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity. Leuk. Lymphoma 47, 1454–1458 (2006).